secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001193125-22-169252
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero pays $54.5M to terminate HCR revenue interest agreement, regains Tebi asset rights
--------------------------------------------------------------------------------

- Cash payment of $54.5M (exact $54,484,895) on June 7, 2022 to terminate HCR financing agreement and release all liens.
- All rights to tebipenem (Tebi) assets revert to Spero; company previously ceased Tebi commercialization on May 3, 2022.
- Contingent additional payment of up to $10M+ if a change of control occurs by Dec 31, 2022, based on equity value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522169252/0001193125-22-169252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522169252/d271182d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-169252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer